Press Releases
"Chairman Schiff has engaged in an assault on the already one-sided process. Based on the publicly available transcripts, it appears Chairman Schiff has worked in concert with select disgruntled bureaucrats to withhold evidence from Intelligence Committee Republicans, this Committee, and the American people.""In light of how Chairman Schiff is conducting the impeachment process and pursuant to Section III of H. Res. 660, all materials in the custody of the Intelligence Committee should be transmitted immediately to this Committee..."
"In spite of how important this issue is to consumers and businesses, this committee dragged its feet, and, instead, fixated on going after President Trump in an attempt to undo the 2016 election. That nonsense is now taking place in other committees rather than our own.
"Everyone knows that I believe in a strong patent system — that it’s essential to our economy, creating jobs and keeping America the world’s technology leader. Patents may be most important to the pharmaceutical and biologic industries. Without patents, companies cannot justify the tremendous investment needed to develop and bring to market the life-saving and life-improving innovations American companies offer patients in this country each year."
"The Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 strikes a good balance by giving the FTC the clear authority to prosecute cases in which a company has engaged in product hopping, without disincentivizing innovation to improve patient care.
"Growers are increasingly turning to the H-2A visa program to get the temporary labor they need, but the program needs reform. The agricultural industry wants and deserves a streamlined program that provides more certainty as to the temporary labor needed to sustain their businesses.
"H-2A users have asked Congress for many reforms of the H-2A program. Unfortunately, despite its proponents’ claims, H.R. 5038 doesn’t fix many of the issues with the program, and, in some cases, the bill makes the problems worse."
"With all the marijuana-related bills pending this Congress — including the bipartisan STATES Act — you have unfortunately chosen to markup the MORE Act today. This bill is nearly devoid of bipartisan support, and it fails to address many critical issues surrounding the cultivation, distribution, sale and use of marijuana."
" . . . the Federal Circuit continues to make decisions that illustrate what a mess the U.S. patent system has become. . . . The [Patent Eligibility Test] has upended confidence in patents in all industries from software and biotech innovations to mechanical inventions. Sadly, this begs the question: Are any patents safe from attack on eligibility grounds? A cloud of uncertainty hangs over almost every issued patent, significantly raising risks for those who invest in research and development."
"Innovation and competition in the pharmaceutical market are key to lowering prescription drug costs. Anticompetitive tactics like product hopping are hurting American families, who are struggling to pay for expensive pharmaceuticals. The Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 would disincentivize pharmaceutical companies from abusing our patent system in order to maintain control over the pharmaceutical market."
". . . this Democrat impeachment crusade lacks the due process protections afforded in all past presidential impeachments, including those protections afforded to President Clinton by Republicans. It is an unfair process for many other reasons, chief among them the fact that minority questions are not being answered in depositions and the President’s counsel has had no voice in the fact-gathering phase of this impeachment inquiry."